Cited by 379Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Open access

Boonen, Steven, Reginster, Jean-Yves, Kaufman, Jean-Marc, Lippuner, Kurt, Zanchetta, Jose, Langdahl, Bente, Rizzoli, Rene, Lipschitz, Stanley, Dimai, Hans Peter, Witvrouw, Richard, Eriksen, Erik, Brixen, Kim, Russo, Luis, Claessens, Frank, Papanastasiou, Philemon, Antunez, Oscar, Su, Guoqin, Bucci-Rechtweg, Christina, Hruska, Josef, Incera, Elodie, Vanderschueren, Dirk, Orwoll, Eric·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1204061

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. RESULTS: The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P=0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P=0.03) and less height loss (P=0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). CONCLUSIONS: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1204061

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,822
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citation
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citation
Mortality after all major types of osteoporotic fracture in men and women: an observational study
Nguyen, T. V., Schneider, D. L., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men
Haentjens, P., Magaziner, J., Colon-Emeric, C. S., Vanderschueren, D., Milisen, K., Velkeniers, B., & Boonen, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-6-201003160-00008 · Cited by 1,420
Prevalence of low femoral bone density in older U.S. women from NHANES III
Looker, A. C., Johnston, C. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., & Lindsay, R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100517 · Cited by 1,379
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III
Looker, A. C., ORWOLL, E. S., Johnston, C. C., Lindsay, R., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., & Heyse, S. P. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.11.1761 · Cited by 1,052
Alendronate for the Treatment of Osteoporosis in Men
ORWOLL, E. S., Ettinger, M. P., Weiss, S. R., Miller, P. D., Kendler, D. L., Graham, J., Adami, S., Weber, K., Lorenc, R. S., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 971
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures
Black, D. M., Arden, N., Palermo, L., Pearson, J., & Cummings, S. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.821 · Cited by 792
The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis
ORWOLL, E. S., Scheele, W. H., Paul, S., Adámi, S., Syversen, U., Díez‐Pérez, A., Kaufman, J.-M., Clancy, A., & Gaich, G. A. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.9 · Cited by 773
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
Delmas, P. D., Genant, H. K., Crans, G., Stock, J. L., Wong, M., Siris, E. S., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 536
Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00307 · Cited by 436
Summarizing historical information on controls in clinical trials
Neuenschwander, B. E., Capkun-Niggli, G., Branson, M., & Spiegelhalter, D. J. (2010) · Clinical Trials · doi:10.1177/1740774509356002 · Cited by 398
Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS)
Lunt, M., O’Neill, T. W., Felsenberg, D., REEVE, J., Kanis, J. А., Cooper, C. C., & Silman, A. J. (2003) · Bone · doi:10.1016/s8756-3282(03)00248-5 · Cited by 213
Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study
Boonen, S., ORWOLL, E. S., Wenderoth, D., Stoner, K. J., Eusebio, R. A., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081214 · Cited by 192
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study
ORWOLL, E. S., Miller, P. D., Adachi, J. D., Brown, J. P., Adler, R. A., Kendler, D. L., Bucci-Rechtweg, C. M., Readie, A., Mesenbrink, P. G., & Weinstein, R. S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.119 · Cited by 185
The near absence of osteoporosis treatment in older men with fractures
Feldstein, A. C., Nichols, G. A., ORWOLL, E. S., Elmer, P. J., Smith, D. H., Herson, M., & Aickin, M. G. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1950-0 · Cited by 139
Efficacy and safety of monthly ibandronate in men with low bone density
ORWOLL, E. S., Binkley, N., Lewiecki, E. M., Gruntmanis, U., Fries, M. A., & Dašić, G. (2010) · Bone · doi:10.1016/j.bone.2009.12.034 · Cited by 102
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence
Roerholt, C., Eiken, P., & Abrahamsen, B. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0651-x · Cited by 83
Osteoporosis and vertebral fractures in men aged 60–74 years
Frost, M., Wraae, K., Abrahamsen, B., Høiberg, M., Hagen, C., Andersen, M., & Brixen, K. (2012) · Age and Ageing · doi:10.1093/ageing/afr170 · Cited by 47
Severity of vertebral fracture and risk of hip fracture: a nested case–control study
Puisto, V., Heliövaara, M., Impivaara, O., Jalanko, T., Kröger, H., Knekt, P., Aromaa, A. J., Rissanen, H. A., & Helenius, I. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1195-4 · Cited by 35
Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC)
Hilner, J. E., Perdue, L., Sides, E. G., Pierce, J. J., Wägner, A. M., Aldrich, A., Loth, A., Albret, L., Wagenknecht, L. E., Nierras, C. R., et al. (2010) · Clinical Trials · doi:10.1177/1740774510373497 · Cited by 35

Flagged first, then by citations

Sorted by citations

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Khan, A. A., Morrison, A. D., Hanley, D. A., Felsenberg, D., McCauley, L. K., O’Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,360
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J. E., Cooper, A., Cooper, C. C., Gittoes, N. J. L., Gregson, C. L., Harvey, N. C., Hope, S., Kanis, J. А., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 865
Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of physicians
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, R. A., Fuleihan, G. E., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J.-A., Favus, M. J., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 689
Screening for Osteoporosis to Prevent Fractures
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.7498 · Cited by 668

See all 379

Authors: Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., Incera, E., Vanderschueren, D., & Orwoll, E.
Affiliations: KU Leuven (BE)
University of Liège (BE)
Ghent University (BE)
University of Bern (CH)
Aarhus University Hospital (DK)
Medical University of Graz (AT)
Ziekenhuis Oost-Limburg (BE)
University of Oslo (NO)
University of Southern Denmark (DK)
Novartis (Switzerland) (CH)
Oregon Health & Science University (US)
ORCID: Reginster, Jean-Yves
Kaufman, Jean-Marc
Lippuner, Kurt
Langdahl, Bente
Dimai, Hans Peter
Eriksen, Erik
Claessens, Frank
Bucci-Rechtweg, Christina
Incera, Elodie
Vanderschueren, Dirk
Orwoll, Eric
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11
Volume: 367
Issue: 18
Pages: 1714-1723
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1204061
OpenAlex: W2123816368
Cited by: 359
References: 30
Citations by year: 2026: 17 · 2025: 24 · 2024: 23 · 2023: 21 · 2022: 25 · 2021: 25 · 2020: 26 · 2019: 24 · 2018: 30 · 2017: 21 · 2016: 28 · 2015: 23 · 2014: 29 · 2013: 36 · 2012: 5
FWCI: 32.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Archive ouverte UNIGE (University of Geneva) (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
BORIS (University Library Bern) (submittedVersion, other-oa)
IRIS (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Open Access CRIS of the University of Bern
Funders: U.S. Department of Justice
Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Teva Pharmaceutical Industries
Danone
University of Bern
Union Chimique Belge
Daiichi-Sankyo
Novo Nordisk
Servier
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: zoledronic acid, male osteoporosis, vertebral fractures, fracture risk reduction, bisphosphonates, androgen deficiency, bone mineral density, bone turnover markers, height loss
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Analysis of Variance, Diphosphonates, Double-Blind Method, Humans, Hypogonadism, Imidazoles, Male, Middle Aged, Osteoporosis, Risk, Testosterone, Bone Density, Logistic Models, Spinal Fractures, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks